Literature DB >> 7155992

Mechanisms of action of androgens and antiandrogens: effects of antiandrogens on translocation of cytoplasmic androgen receptor and nuclear abundance of dihydrotestosterone.

T W Callaway, N Bruchovsky, P S Rennie, T Comeau.   

Abstract

The effects of antiandrogens on the translocation of androgen receptor and the accumulation of nuclear dihydrotestosterone in rat ventral prostate were investigated. Using an isotope-exchange assay and radioimmunoassay it was found that 1 hr after the injection of 70 nmol of dihydrotestosterone into 1-day castrated rats, 19,000 +/- 2.350 (mean +/- SE) receptor molecules and 99,300 +/- 8,200 molecules of dihydrotestosterone were recovered per nucleus. When equivalent doses of antiandrogens were substituted for dihydrotestosterone only 0-1,500 receptor molecules were translocated. After injection of antiandrogens followed 1 hr later by injection of dihydrotestosterone, the inhibition of translocation given by the reduction in the mean numbers of molecules of receptor and dihydrotestosterone, respectively, was as follows: 17 beta-estradiol (0, 0); megestrol acetate (2000, 0); diethylstilbestrol (6000, 4000); cyproterone acetate (5500, 27000); flutamide (10000, 29000); R2956 (10000, 28000). With the exception of the effect of cyproterone acetate on receptor translocation, the reductions produced by the latter three antiandrogens were all statistically significant (P less than 0.5). Since less than 20% of the dihydrotestosterone in the nucleus is bound to receptor in dihydrotestosterone-treated rats, and since the concentrations of receptor and dihydrotestosterone are unequally affected by some antiandrogens, we infer that the nuclear abundance of dihydrotestosterone may be regulated in part through nonreceptor-mediated processes.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7155992     DOI: 10.1002/pros.2990030609

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  5 in total

Review 1.  Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.

Authors:  C Mahler; J Verhelst; L Denis
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

2.  Side gland of Suncus murinus as a new model of sebaceous gland: 5 alpha-reductase, androgen receptor, and nuclear androgen content in male and female animals.

Authors:  S Komada; S Itami; S Kurata; S Takayasu
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

3.  Morphofunctional study of the effects of fetal exposure to cyproterone acetate on the hypothalamo-pituitary-gonadal axis of adult rats.

Authors:  G L Rossi; G E Bestetti; M J Reymond; T Lemarchand-Béraud
Journal:  Exp Brain Res       Date:  1991       Impact factor: 1.972

4.  Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy.

Authors:  Yoko Omoto; Takashi Takeshita; Yutaka Yamamoto; Mutsuko Yamamoto-Ibusuki; Mitsuhiro Hayashi; Aiko Sueta; Saori Fujiwara; Tetsuya Taguchi; Hirotaka Iwase
Journal:  Springerplus       Date:  2015-03-05

Review 5.  Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens.

Authors:  Yusuke Ito; Marianne D Sadar
Journal:  Res Rep Urol       Date:  2018-02-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.